A biotechnology company focused on developing better therapeutics for neurological conditions, Psilera, has closed an $8.8M Seed funding round. The investment marks a significant step for the firm, which has been dedicated to early-stage drug discovery and development since its founding in 2019.
Psilera was established by scientists with a mission to address disorders such as dementia, addiction, and various mental health challenges. Its team comprises experts across synthetic chemistry, pharmacology, clinical development, and business development, driving its research forward.
